8 completed, 4 recruiting, 2 not yet recruiting, 2 terminated. 22 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 22 | Completed 8, Recruiting 4, Not yet recruiting 2, Terminated 2, Unknown 2, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1 |
Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CS-206 in Patients With Sickle Cell Disease CS-206 - Sickle Cell Disease | Early Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 5 | 2026-09-30 | 2026-05-15 |
| YOLT-204 in Patients With Hemoglobinopathies YOLT-204 - Hemoglobinopathies (Transfusion-dependent β-thalassemia and Sickle Cell Disease) | Early Phase 1 | Not yet recruiting | Guangzhou Women and Children's Medical Center | 18 | 2025-09-30 | 2025-09-24 |
| CS-206 in Patients With Sickle Cell Disease CS-206 - Sickle Cell Disease | Early Phase 1 | Recruiting | CorrectSequence Therapeutics Co., Ltd | 5 | 2024-09-02 | 2026-02-10 |
| Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling Biotin-labeled red blood cells - Sickle Cell Disease, Thalassemia | Early Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 100 | 2024-05-17 | 2026-09-28 |
| CS-101 in Patients With β-thalassemia CS-101 - Beta-Thalassemia | Early Phase 1 | Enrolling by invitation | CorrectSequence Therapeutics Co., Ltd | 10 | 2024-03-19 | 2026-06-09 |
| Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major CS-101 injection - Beta-Thalassemia | Early Phase 1 | Completed | Children's Hospital of Fudan University | 2 | 2023-11-07 | 2026-05-15 |
| Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease RM-004 - Alpha Thalassemia Hemoglobin H Constant Spring, Hemoglobinopathies | Early Phase 1 | Recruiting | The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | 5 | 2023-10-08 | 2024-06-03 |
| A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia CS-101 - Beta-Thalassemia | Early Phase 1 | Completed | CorrectSequence Therapeutics Co., Ltd | 5 | 2023-08-26 | 2026-02-12 |
| A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT] GMCN-508B (LentiRed) - Transfusion Dependent Beta-Thalassemia | Early Phase 1 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 5 | 2023-02-22 | 2023-05-09 |
| Alternative Dosing And Prevention of Transfusions (ADAPT) Hydroxyurea - Sickle Cell Disease | Early Phase 1 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 100 | 2022-06-16 | 2026-04-09 |
| Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease Biotin label - Sickle Cell Disease, Sickle Cell Anemia | Early Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 22 | 2021-04-19 | 2024-02-13 |
| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2020-12-29 | 2024-10-24 | |
| RHD Genotype Matched Red Cells for Anti-D D+ RH genotype matched red cell units for transfusion - Sickle Cell Disease, Anti-D Antibodies | Early Phase 1 | Completed | Children's Hospital of Philadelphia | 5 | 2020-07-08 | 2025-05-02 |
| A Dose-Finding Study of AG-348 in Sickle Cell Disease AG-348 - Sickle Cell Disease | Early Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 17 | 2019-07-11 | 2022-07-12 |
| iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations iHSCs treatment group - Thalassemia | Early Phase 1 | Unknown | Allife Medical Science and Technology Co., Ltd. | 12 | 2019-01-01 | 2018-11-05 |
| Stem Cell Transplant in Patients With Severe Sickle Cell Disease Alemtuzumab, Total Body Irradiation, Sirolimus - Sickle Cell Disease | Early Phase 1 | Terminated | Kathleen Dorritie | 1 | 2018-03-29 | 2022-06-28 |
| Fetal Hemoglobin Induction Treatment Metformin Metformin, Questionnaires - Sickle Cell Anemia, Sickle Cell Disease | Early Phase 1 | Completed | Baylor College of Medicine | 37 | 2017-03-02 | 2023-10-12 |
| Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With Thalassemia Colla corii asini - Thalassemia | Early Phase 1 | Unknown | Yanfang Li | 90 | 2015-03-01 | 2016-05-13 |
| Androgen Regulation of Priapism in Sickle Cell Disease Transdermal Androgel - Priapism, Sickle Cell Disease | Early Phase 1 | Withdrawn | Johns Hopkins University | 2014-03-01 | 2017-01-19 | |
| Novel Dose Escalation to Predict Treatment With Hydroxyurea Hydroxyurea - Sickle Cell Disease | Early Phase 1 | Completed | Baylor College of Medicine | 70 | 2013-10-01 | 2020-11-18 |
Showing 20 of 22. Sign in to see all of them.
Anemia, Sickle Cell (15) · beta-Thalassemia (5) · Thalassemia (3) · Hematologic Diseases (2) · Genetic Diseases, Inborn (1) · Hypogonadism (1) · Kidney Diseases (1) · Priapism (1) · Sickle Cell Trait (1) · alpha-Thalassemia (1)
Anemia (22) · Anemia, Hemolytic (22) · Anemia, Hemolytic, Congenital (22) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22) · Hemic and Lymphatic Diseases (22) · Genetic Diseases, Inborn (21) · Hematologic Diseases (20) · Thalassemia (6) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1)
Hydroxyurea (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Blood Transfusion (1) · Bortezomib (1) · Busulfan (1) · CT-P10 (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Dexamethasone (1) · Hematopoietic Stem Cell Transplantation (1) · Losartan (1) · Metformin (1) · Mycophenolic Acid (1) · Plasma Exchange (1)
CorrectSequence Therapeutics Co., Ltd (3) · Baylor College of Medicine (2) · Children's Hospital of Fudan University (2) · Emory University (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Allife Medical Science and Technology Co., Ltd. (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Hospital of Philadelphia (1) · First Affiliated Hospital of Guangxi Medical University (1) · Guangzhou Women and Children's Medical Center (1) · Johns Hopkins University (1) · Kathleen Dorritie (1) · M.D. Anderson Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1) · The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army (1)
United States (10) · China (9) · Uganda (1)
Yongrong Lai, M.D. (3) · John F Tisdale, M.D. (2) · Xiaowen Zhai, M.D. (2) · Alex George, MD, PhD (1) · Ann Haight, M.D. (1) · Arthur L Burnett, MD, MBA (1) · Kathleen Dorritie, MD (1) · Kris M Mahadeo (1) · Marianne Yee, MD (1) · Russell Ware, MD, PhD (1) · Stella Chou, MD (1) · Swee Lay Thein, M.D. (1) · Titilope Fasipe, MD (1) · Xinhua Zhang, MD (1)
PMID 42705233, PMID 35576529, PMID 38181784, PMID 39172743, PMID 39265169, PMID 40222814, PMID 40441700, PMID 41809202, PMID 41951736, PMID 42376265
R01HL147879 (1)